$373MSeries D, 28 July 2025
Funds Phase 2 trials of ML-007C-MA in schizophrenia and Alzheimer's psychosis.
- Amount
- $373M
- Stage
- Series D
- Announced
- 28 July 2025
- Lead
- Forbion
- Other investors
- Goldman Sachs Alternatives, Sanofi, T. Rowe Price, Avego BioScience, Novo Holdings, 5AM Ventures, Blue Owl
- Use of funds
- Funds Phase 2 trials of ML-007C-MA in schizophrenia and Alzheimer's psychosis.
- Checked
- Announced by the company
- Sources
- MapLight raises $372.5M forbion.com
MapLight raises $372.5M pulse2.com